EU Bans Levamisolo: Parasitic Infection Drugs Pulled Over Brain Risk

European health authorities have recommended the withdrawal of all medications containing levamisole from the market. The decision, made by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), stems from concerns that the benefits of the drug no longer outweigh the risks.

Levamisole and the Risk of Leucoencephalopathy

The PRAC’s recommendation follows a safety review that linked levamisolo to leucoencephalopathy, a rare but severe neurological condition affecting the brain’s white matter. Symptoms of this condition can appear even after a single dose of levamisole and may manifest from one day to several months after treatment.

Which Medications Are Affected?

The withdrawal applies to antielmintic medications – those used to treat parasitic worm infections – as well as systemic antiparasitic medications used for mild infections. Specifically, products containing levamisole in monoterapia for human use are included in this action.

Did You Know? The PRAC’s review found no effective strategies to reduce the risk of leucoencephalopathy associated with levamisole, nor were any patient categories identified as being more susceptible.

According to the EMA, the review did not identify any ways to use the drug safely. The medications are primarily prescribed for non-serious conditions, such as common parasitic infestations, for which safer therapeutic alternatives are available.

What Happens Next?

The EMA has instructed that medications containing levamisole will no longer be available in the European Union. The PRAC has also approved a communication to physicians, pharmacists, and other healthcare professionals to inform them of the risk of leucoencephalopathy and the decision to withdraw the drug. This information will be disseminated through marketing authorization holders and published in national health registries across EU countries.

Expert Insight: The EMA’s decision highlights the ongoing commitment to monitoring the safety of medications even after they have been in use for some time. The identification of a serious, unpredictable risk, even with a relatively uncommon drug, underscores the importance of robust pharmacovigilance systems.

Frequently Asked Questions

What is leucoencephalopathy?

Leucoencephalopathy is a rare but severe condition that damages the white matter of the brain. Symptoms can appear after a single dose of levamisole and may take days or months to manifest.

Which types of medications are being withdrawn?

Antielmintic medications (for parasitic worms), systemic antiparasitic medications for mild infections, and products containing levamisole in monoterapia for human use are all subject to the withdrawal.

What prompted this decision?

The decision was prompted by a safety review conducted by the PRAC, which concluded that the benefits of levamisole no longer outweigh the risks due to the potential for leucoencephalopathy.

As health authorities prioritize patient safety, how might this decision influence the future of antiparasitic drug development and monitoring?